News & Perspective

Jul 07, 2010

Jul 07, 2010

Non-vaccine aid for needy nations' pandemic response falls short

(CIDRAP News) – While donor countries and organizations have responded well to the need for pandemic flu vaccine for developing countries, the level of giving for other pandemic response efforts in needy countries so far has fallen short, the World Health Organization (WHO) said in a recent report.

Oct 29, 2008

Oct 29, 2008

Experts stress vigilance over emerging, unpredictable diseases

See related article posted today: "US urged to launch major campaign against emerging diseases"

– WASHINGTON, DC (CIDRAP News) – Health authorities must remain alert to new and renascent disease threats, experts warned this week at an international medical meeting.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Oct 26, 2007

Oct 26, 2007

THE PANDEMIC VACCINE PUZZLE Part 2: Vaccine production capacity falls far short

Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Jan 20, 2006

Jan 20, 2006

Report discourages use of antivirals for seasonal flu

Jan 20, 2005 (CIDRAP News) – Researchers who analyzed numerous clinical trials concluded that the two newest antiviral drugs for influenza, oseltamivir (Tamiflu) and zanamivir (Relenza), should not routinely be used against seasonal flu—a recommendation flatly rejected by the manufacturer of oseltamivir.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»